相关临床试验
1206
78 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1851
进行中（未招募）
37
3.1%
已完成
782
64.8%
Enrolling By Invitation
3
0.3%
No Longer Available
1
0.1%
尚未招募
38
3.1%
招募中
161
13.3%
暂停
3
0.3%
终止
66
5.5%
Unknown
4
0.3%
撤回
111
9.2%
暂无批准数据
- A multi-institutional team discovered MWAC-3634, a small molecule that blocks Ebola virus entry by stabilizing the viral entry protein rather than destabilizing it. - Screened from roughly 4.73 billion molecules using DNA-encoded chemistry, the compound inhibited authentic Ebola virus with an IC50 of 0.65 nM. - In a lethal mouse model, 85.7% of orally treated mice survived versus 28.6% of controls, with 100% survival among injected mice. - MWAC-3634 showed 69% oral bioavailability, but researchers caution it remains experimental and has not been tested or approved for human use.
- NeuroOne received ISO 13485 certification, enabling international commercialization of its OneRF Brain and Trigeminal Neuralgia Ablation Systems and Evo diagnostic lines. - Third-quarter fiscal 2026 product revenue reached $2.0 million, up 16% year over year, with product orders of $2.7 million, up 43%. - The Journal of Neurosurgery published a Mayo Clinic Jacksonville study showing OneRF procedures may be performed without interfering with implanted neuromodulation hardware. - NeuroOne's robotic-assisted StereoCED intracranial drug delivery platform is expected to be ready for investigational human clinical studies by the end of September.
- Scientists at the University of Minnesota constructed a synthetic cell called SpudCell from nonliving chemical components that can grow, replicate its DNA, and divide for approximately five generations. - The cell contains 150 to 200 molecules with a 90,000-base-pair genome and requires external feeding of ribosomes and nutrients to function, as it cannot survive independently. - Researchers founded Biotic, a public-benefit institution, to make the core technology openly available as a shared global standard for synthetic cell biology. - Experts describe the work as a major breakthrough in synthetic biology that could eventually enable programmable cells for drug manufacturing, cancer treatments, and carbon capture.
- New research published in The Journal of Immunology identifies biomarkers of a distinct immune profile that could identify trauma patients at risk for chronic critical illness (CCI) upon ICU admission. - Contrary to long-held beliefs about immune exhaustion, the study reveals that CCI is driven by immune overactivity and dysfunction, including elevated neutrophils, Th17 cells, IFNγ, and IL-17A. - IL-17A emerged as the most informative marker distinguishing CCI patients, with some showing elevated levels as early as day 1 in the ICU, suggesting almost immediate immune dysregulation. - Developing a test for this immune profile could allow clinicians to tailor patient care, quickening recovery time and potentially saving lives.
- TransCode Therapeutics has initiated a Phase 2a clinical trial for TTX-MC138 in ctDNA-positive colorectal cancer patients following successful completion of Phase 1a studies. - The Phase 1a trial demonstrated strong safety profile with no dose-limiting toxicities and achieved 64% stable disease rate in evaluable metastatic cancer patients. - TTX-MC138 represents a first-in-class therapeutic targeting microRNA-10b, with three patients continuing treatment for over 14 cycles showing durable disease control. - The Phase 2a trial will enroll up to 45 colorectal cancer patients with minimal residual disease, conducted through the PRE-I-SPY platform in collaboration with leading cancer centers.
- BioVersys has entered an exclusive collaboration and license agreement with Hackensack Meridian Health to jointly develop ansamycin antimicrobial candidates targeting difficult-to-treat non-tuberculous mycobacteria (NTM) infections. - The partnership combines BioVersys' proprietary Ansamycin Chemistry platform with advanced lead molecules from HMH's Center for Discovery and Innovation, strengthening the pool of orally bioavailable anti-NTM candidates. - NTM pulmonary disease affects approximately 250,000 people annually with current cure rates as low as 30-50%, representing a significant unmet medical need for vulnerable populations including cystic fibrosis patients. - The collaboration aims to address the growing crisis of NTM infections, which have increased from 3.3% to 22.6% among cystic fibrosis patients, with some pathogens associated with up to 50% mortality rates.
- Verve Medical has treated the first patient in its randomized, double-blinded U.S. pilot trial testing renal pelvic denervation (RPD) technology for uncontrolled hypertension. - The trial builds on promising TUSK feasibility results showing approximately 20 mmHg reduction in systolic blood pressure among treated patients through one year of follow-up. - The RPD therapy uses radiofrequency energy delivered through the urinary tract to target renal nerves, offering a differentiated approach compared to traditional catheter-based renal denervation methods. - The pilot study will enroll 60 patients across 10 U.S. clinical sites, with participants randomized to receive either RPD therapy or a sham procedure.
- The MAGNETOM Free.Max Dental Edition, developed by Dentsply Sirona and Siemens Healthineers, becomes the first dental-dedicated MRI system to receive FDA clearance in the United States. - Clinical trials validated the system's effectiveness across multiple dental specialties including endodontics, periodontics, TMJ disorders, tooth extraction, and orthodontics with radiation-free imaging capabilities. - The ddMRI system demonstrates ability to differentiate active inflammation from healthy tissue, assess tooth pulp vitality non-invasively, and visualize dental structures with advanced soft tissue contrast in under 20 minutes. - This breakthrough technology addresses diagnostic limitations of current imaging modalities by providing superior soft tissue characterization without ionizing radiation exposure.
- Bioxytran has executed a sponsored research agreement with the University of Minnesota to advance understanding of polysaccharide and oligosaccharide interactions with biological targets. - The collaboration will utilize advanced nuclear magnetic resonance spectroscopy under Dr. Kevin Mayo's direction to analyze carbohydrate-binding interactions and structural conformations. - The research program runs through early 2027 and aims to strengthen the scientific foundation for Bioxytran's carbohydrate-based technology platform spanning glycovirology, hypoxia, and degenerative diseases. - Findings may guide future therapeutic development strategies and inform preclinical research initiatives for novel carbohydrate-based treatments.
- Scripps Research scientists discovered that ruxolitinib, an approved JAK inhibitor, significantly enhances checkpoint inhibitor effectiveness when used in combination therapy for cancer treatment. - A phase I clinical trial in 19 Hodgkin lymphoma patients who failed checkpoint inhibitor therapy showed 87% survival and 46% progression-free rates at two years with ruxolitinib-nivolumab combination. - The combination therapy works by modulating myeloid cells and reducing immunosuppressive factors, leading to increased T-cell and natural killer cell production. - Researchers plan to test the approach in other cancer types and explore additional JAK inhibitors for potentially broader therapeutic applications.
